Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

This study has been completed.
Sponsor:
Information provided by:
Centocor, Inc.
ClinicalTrials.gov Identifier:
NCT00230529
First received: September 29, 2005
Last updated: June 8, 2011
Last verified: August 2010